Literature DB >> 6785814

Effect of 5,7-dihydroxytryptamine on serotonergic control of prolactin secretion and behavior in rats.

C M Kuhn, R A Vogel, R B Mailman, R A Mueller, S M Schanberg, G R Breese.   

Abstract

The intracisternal administration of 5,7-dihydroxytryptamine (5,7-DHT) to rats resulted in a potentiated response to 5-hydroxytryptophan (5-HTP) when the animals were tested 30 days later. The 5-HTP-induced changes include elevation of serum prolactin, decrease in operant responding, and the magnitude of the "serotonin behavioral syndrome" observed after 5-HTP administration. The serotonin concentration in brains of 5,7-DHT-treated animals reached maximum earlier and remained elevated longer than that of controls following administration of 5-HTP. Brain norepinephrine and dopamine concentration were not affected by 5-HTP in either group of animals. The increase in serum prolactin concentration elicited by administration of the serotonergic agonists quipazine or 5-methoxy-N,N-dimethyltryptamine and by the serotonin uptake inhibitor fenfluramine also was potentiated by pretreating rats with 5,7-DHT. These data suggest that both serotonergic receptor supersensitivity and the absence of presynaptic uptake sites contribute to the enhanced responses to 5-HTP occurring in rats previously treated with 5,7-DHT. The findings further demonstrate that both behavioral and hormonal measures can be used to assess the sensitivity of serotonergic receptors and indicate that 5,7-DHT may be useful in evaluating the role of serotonergic neurons in neuroendocrine function.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6785814     DOI: 10.1007/BF00429216

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

1.  The effect of a serotonin uptake inhibitor (Lilly 110140) on the sercretion of prolactin in the rat.

Authors:  L Krulich
Journal:  Life Sci       Date:  1975-10-10       Impact factor: 5.037

2.  Identification and assay of serotonin in brain.

Authors:  D F BOGDANSKI; A PLETSCHER; B B BRODIE; S UNDENFRIEND
Journal:  J Pharmacol Exp Ther       Date:  1956-05       Impact factor: 4.030

3.  Effects of serotonin neurotoxins on pituitary hormone release.

Authors:  J A Clemens
Journal:  Ann N Y Acad Sci       Date:  1978-06-12       Impact factor: 5.691

4.  Effects of serotonin precursors and melatonin on serum prolactin release in rats.

Authors:  K H Lu; J Meites
Journal:  Endocrinology       Date:  1973-07       Impact factor: 4.736

5.  Release of ( 3 H)dopamine by L-5-hydroxytryptophan.

Authors:  L K Ng; T N Chase; R W Colburn; I J Kopin
Journal:  Brain Res       Date:  1972-10-27       Impact factor: 3.252

6.  5,7-Dihydroxytryptamine as a tool for the morphological and functional analysis of central 5-hydroxytryptamine neurons.

Authors:  J Daly; K Fuxe; G Jonsson
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-01

7.  5,7-dihydroxytryptamine: improvement in chemical lesioning of indoleamine neurons in the mammalian brain.

Authors:  H G Baumgarten; L Lachenmayer
Journal:  Z Zellforsch Mikrosk Anat       Date:  1972

8.  Effects of biogenic amines and TRH on release of prolactin and TSH in the rat.

Authors:  H J Chen; J Meites
Journal:  Endocrinology       Date:  1975-01       Impact factor: 4.736

9.  Activity, avoidance learning and regional 5-hydroxytryptamine following intra-brain stem 5,7-dihydroxytryptamine and electrolytic midbrain raphe lesions in the rat.

Authors:  S A Lorens; H C Guldberg; K Hole; C Köhler; B Srebro
Journal:  Brain Res       Date:  1976-05-21       Impact factor: 3.252

10.  Action of fenfluramine on monoamine stores of rat tissues.

Authors:  E Costa; A Groppetti; A Revuelta
Journal:  Br J Pharmacol       Date:  1971-01       Impact factor: 8.739

View more
  4 in total

1.  5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

2.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

Authors:  G A Ricaurte; U D McCann
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

3.  5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; M Oakes; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

Review 4.  The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).

Authors:  Johannes T Reckweg; Malin V Uthaug; Attila Szabo; Alan K Davis; Rafael Lancelotta; Natasha L Mason; Johannes G Ramaekers
Journal:  J Neurochem       Date:  2022-03-08       Impact factor: 5.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.